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BASIC AND TRANSLATIONAL SCIENCE
Blocking CXCL9 Decreases HIV-1 Replication and Enhances
the Activity of Prophylactic Antiretrovirals in Human
Cervical Tissues
Sherrill L. Macura, PhD,*† Melissa J. Lathrop, PhD,*‡ Jiang Gui, PhD,§ Gustavo F. Doncel, MD, PhD,k
Susana N. Asin, PhD,*¶ and Christiane Rollenhagen, PhD*#
Objectives: The interferon-gamma–induced chemokine CXCL9 is
expressed in a wide range of inflammatory conditions including
those affecting the female genital tract. CXCL9 promotes immune
cell recruitment, activation, and proliferation. The role of CXCL9 in
modulating HIV-1 infection of cervicovaginal tissues, a main portal
of viral entry, however, has not been established. We report a link
between CXCL9 and HIV-1 replication in human cervical tissues
and propose CXCL9 as a potential target to enhance the anti–HIV-1
activity of prophylactic antiretrovirals.
Design: Using ex vivo infection of human cervical tissues as a model
of mucosal HIV-1 acquisition, we described the effect of CXCL9
neutralization on HIV-1 gene expression and mucosal CD4+ T-cell
activation. The anti-HIV-1 activity of tenofovir, the leading mucosal
pre-exposure prophylactic microbicide, alone or in combination with
CXCL9 neutralization was also studied.
Methods: HIV-1 replication was evaluated by p24 ELISA. HIV-1
DNA and RNA, and CD4, CCR5, and CD38 transcription were
evaluated by quantitative real-time polymerase chain reaction. Fre-
quency of activated cervical CD4+ T cells was quantified using
fluorescence-activated cell sorting.
Results: Antibody blocking of CXCL9 reduced HIV-1 replication
by decreasing mucosal CD4+ T-cell activation. CXCL9 neutralization
in combination with suboptimal concentrations of tenofovir, possibly
present in the cervicovaginal tissues of women using the drug
inconsistently, demonstrated an earlier and greater decrease in
HIV-1 replication compared with tissues treated with tenofovir alone.
Conclusions: CXCL9 neutralization reduces HIV-1 replication
and may be an effective target to enhance the efficacy of
prophylactic antiretrovirals.
Key Words: CXCL9, HIV-1 replication, cervical tissues, pro-
phylactic microbicides
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INTRODUCTION
Immune cell activation by HIV-1 is essential to mount
an effective host immune response. This process however
also provides an immunological microenvironment that drives
viral replication and disease progression in HIV-1–infected
individuals.1–3
HIV-1 replication is regulated by a complex network of
immune factors produced by a variety of hematopoietic and
nonhematopoietic cells. Although immune factors with
stimulatory and inhibitory effects on HIV-1 replication in
peripheral blood mononuclear cells (PBMCs) are expressed at
mucosal sites of HIV-1 exposure, for example, the female
genital tract (FGT), knowledge about their contribution to
HIV-1 replication is limited.4–7
The genital mucosa is populated with T cells, macro-
phages, and dendritic cells expressing the HIV-1 receptor CD4,
and coreceptors CCR5 and CXCR4.8,9 Each of these cell
populations is a potential target for infection; yet, recent
findings identified CD4+ T cells as the main infected cell
population in cervicovaginal tissues.10 Moreover, activated
compared with resting CD4+ T cells are more susceptible to
HIV-1.7,11–13 These findings suggest that HIV-1 induces
inflammatory cytokine production in mucosal CD4+ T cells,
leading to immune cell activation, proliferation, and HIV-1
receptor expression,2,14–16 thereby enhancing HIV-1 infection.7
The relevance of inflammatory cytokines in driving HIV-
1 replication in the FGT is underscored by our previous work
demonstrating that HIV-1 enhances interleukin (IL)-6 expres-
sion in cervical tissues (CTs).17 Higher IL-6 production is
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associated with increased HIV-1 transcription. Evaluating the
impact of a woman’s reproductive phase on HIV-1 replication,
we demonstrated greater expression of pro-inflammatory cyto-
kines and chemokines and enhanced HIV-1 replication in CTs
from postmenopausal women compared with premenopausal
women.7 Regarding the impact of sexually transmitted patho-
gens on HIV-1 infection, specifically herpes simplex virus type
2 (HSV-2), we reported enhanced viral replication in HIV-1/
HSV-2 coinfected CTs compared with HIV-1–infected CTs.18
Greater HIV-1 replication was associated with higher CD4,
CCR5, and CD38 expression and frequency of HIV-1–infected
cells.18 These findings underscore the role of mucosal inflam-
mation and sex hormones in regulating HIV-1 replication.19–22
The identification of factors driving immune cell activa-
tion and HIV-1 replication by HSV-2 is incomplete. Productive
HSV-2 infection of cervical epithelial cells stimulates C-X-C
motif chemokine 9 (CXCL9) expression, which controls viral
infection.23–25 CXCL9 triggers CD4+ T-cell migration, activa-
tion, and proliferation26; yet, the extent to which CXCL9
impacts HIV-1 replication in the genital mucosa is unknown.
Increased CXCL9 expression has been reported in blood,
semen, gut mucosa, and colostrum samples of HIV-infected
individuals.27–29 Furthermore, low CXCL9 expression in the
genital mucosa of HIV-exposed seronegative commercial sex
workers was associated with HIV-1 protection,30 suggesting
that CXCL9 may be a target to decrease HIV-1 replication.
We report on the scope and mechanism of CXCL9
modulation of HIV-1 replication. HIV-1 enhanced CXCL9
expression and blocking CXCL9 decreased HIV-1 replication
in CTs. CXCL9 induction by HIV-1 and decreased HIV-1
replication by CXCL9 neutralization were also observed in
PBMCs, suggesting that immune cells may contribute to
CXCL9 expression and signaling in CTs. CXCL9 neutrali-
zation decreased mucosal immune cell activation, thereby
lowering the number of activated CD4+ T cells.
CXCL9 neutralization enhanced the efficacy of sub-
optimal concentrations of tenofovir (TFV), the leading mucosal
pre-exposure prophylactic microbicide, especially early during
the infection. When used in combination with TFV at
suboptimal concentrations possibly present in poor adherers,
CXCL9 neutralization could further decrease HIV-1 replication
in CTs, a main portal of viral entry.
METHODS
Tissue Samples
CTs were obtained from HIV-1 seronegative women
undergoing hysterectomy at Dartmouth–Hitchcock Medical
Center for benign medical conditions after an institutional review
board–approved protocol. Nonpolarized CTs were established as
described.17,31–33 Using our culture conditions, tissues can be
maintained for until 21 days without significant decrease in
viability, as determined by lactate dehydrogenase viability assay
(Cytotoxicity Detection Kit; Roche, Indianapolis, IN).
HIV-1 Infection
HIV-1 stocks were generated in human PBMCs. Tissues
were infected with 104 cell-free R5-tropic HIV-1BaL, a 50% tissue
culture infectious dose (TCID50)/mL. After overnight incubation
at 37°C, tissues were washed to remove residual input virus (day
0) and cultured for 21 days in Leibovitz L-15 medium (Gibco,
Grand Island, NY) as described.7,17,18 Day 11 and 21 supernatants
were evaluated for HIV-1 p24 antigen by enzyme-linked
immunosorbent assay (ELISA) (PerkinElmer, Boston, MA).
PBMC Isolation and Infection
PBMCs were isolated by Ficoll-Paque Plus (Amersham,
Piscataway, NJ)34 and incubated overnight at 37°C in complete
RPMI-1640 (GIBCO). Next day, cells were resuspended at 2 ·
106 cells per milliliter and infected with one 50 TCID50/mL of
HIV-1BaL. After overnight infection, PBMCs were washed,
resuspended in medium, and cultured for 7 days.
Neutralizing Antibody and TFV Treatment
Of note, 1 mg/mL of either antigen affinity-purified
polyclonal goat neutralizing CXCL9 or isotype control anti-
bodies (abs; R&D systems, Minneapolis, MN) was added to
CTs or PBMCs on day 0, replenished every 3 days, and
maintained in the cultures throughout the experiment. No ab
cytotoxic effects were observed. Tissues were treated with
TFV at either 100 or 10 mg/mL for 6 hours before HIV-1
infection. When indicated, CXCL9 neutralizing or isotype
control abs was added to designated wells on day 0. TFV was
kindly provided by CONRAD (Arlington, VA).
Nucleic Acid Isolation
Genomic DNA and RNA were isolated as previously
described.7,17,18,35
HIV-1 Reverse Transcription and Integration
HIV-1 total DNA and integration were detected by a 2-
step quantitative real-time polymerase chain reaction ampli-
fication as described.35–37
Gene Transcription
HIV-1 RNA and HIV-1 receptor, coreceptor, and immune
cell activation markers’ expression was detected as described.18
Fluorescence–Activated Cell
Sorting Experiments
CTs (8–10 pieces) were digested with collagenase D
at 5 mg/mL in complete L15 for 1 and half hour at 37°C
(Roche Diagnostics, Indianapolis, IN). Single cell suspen-
sions were fixed and stained as described.38 Data were
acquired on a BD FCASCanto II (BD Biosciences, San
Jose, CA) using FACSDiva software (BD Biosciences) and
analyzed with FlowJo version 10.0.7 (Ashland, OR). CD4+
T cells were defined as CD3+ and CD82.10
Statistical Analysis
Our experimental design fits a hierarchical model (depen-
dent observations) to account for repeated measurements, each
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triplicated, within tissues. We included a random intercept for
tissue and triplicates within tissue, in addition to fixed effects for
the day and treatment. Analysis of datasets for HIV-1 reverse
transcription, integration, and p24 containing 2 groups (Isotype
and CXCL9 neutralizing ab)-treated tissues on days 11 and 21
after infection as well as CD4, CCR5, and CD38 RNA
expression on days 3 and 5 after infection was performed by
paired Student t test after logarithmic transformation to achieve
normality. Nontransformed data of CXCL9 expression were
expressed as arithmetic mean values and compared by paired
Student t test. P values of ,0.05 were considered significant.
RESULTS
HIV-1 Enhances CXCL9 Expression and
Blocking CXCL9 Decreases HIV-1 Replication
in CTs
CXCL9 expression is enhanced in the peripheral blood,
semen, and gut mucosa of HIV-1–infected individuals27,29; yet,
modulation of CXCL9 expression by HIV-1 in the FGT remains
to be evaluated. To address whether HIV-1 enhances CXCL9
expression at primary sites of viral exposure, we evaluated
CXCL9 protein levels in uninfected and HIV-1–infected CTs.
CXCL9 levels were expressed as fold increase in HIV-1–infected
tissues compared with uninfected controls set to 1. CXCL9
expression was significantly enhanced by HIV-1 on day 7 (Fig.
1A, P = 0.04) compared with day 4 (P = 0.128) after infection.
To determine if there was a causal relationship between
CXCL9 and HIV-1 replication, we blocked CXCL9 signaling
with a specific neutralizing ab and infected CTs with HIV-1.
We detected a significant decrease in HIV-1 p24 levels
in supernatants from HIV-1–infected CTs treated with CXCL9
neutralizing ab compared with isotype control–treated tissues
on both days 11 (P = 0.009) and 21 (P = 0.027) after infection
(Fig. 1B). Day 11 is one of the earliest time points where we
consistently detect new viral release and HIV-1 DNA expres-
sion. Day 21 is the day when we terminated our experi-
ments.7,18 To ascertain the step in the virus life cycle, we next
tested whether CXCL9 neutralization decreased early events,
that is, viral reverse transcription and integration. We detected
no differences in HIV-1 reverse transcription between tissues
treated with CXCL9 neutralizing or isotype control abs on
either day 11 (P = 0.215) or 21 (P = 0.569) after infection (Fig.
1C). Likewise, CXCL9 neutralization did not alter HIV-1
integration at either time point (Fig. 1D; P = 0.824 and P =
0.698 on days 11 and 21 after infection, respectively).
Blocking CXCL9 Signaling Decreases HIV-1
Receptor and Immune Activation Markers
in CTs
The lack of effect of CXCL9 neutralization on HIV-1
reverse transcription and integration suggests that CXCL9
decreases HIV-1 replication by targeting postintegration
events. CXCL9 stimulates proliferation and activation of
FIGURE 1. HIV-1 induces CXCL9
expression and blocking CXCL9 de-
creases HIV-1 replication in ex vivo
cervical tissues. CXCL9 levels (pg/mL)
(A) in culture supernatants from HIV-
1–infected cervical tissues were
evaluated by ELISA on days 4 and 7
after infection. The results from 15
individual donors assessed in dupli-
cate are shown. For each donor,
CXCL9 levels were expressed as fold
increase in HIV-1–infected tissues
compared with uninfected controls
set to 1. *P , 0.05 for HIV-infected vs.
uninfected cervical tissues. HIV-1 p24
levels (ng/mL) (B), viral reverse tran-
scription (C), and integration (D) in
HIV-1–infected cervical tissues treated
with CXCL9 neutralizing (CXCL9) or
isotype control (ISO) abs were mea-
sured by p24 ELISA (B) or real-time
polymerase chain reaction (C and D)
on days 11 and 21 after infection.
Data from 18 (B), 14 (C), and 16 (D)
individual donors are shown with
each condition evaluated in tripli-
cates. For HIV-1 reverse transcription
and integration, all data were nor-
malized to human b actin. Day 11
values in ISO-treated tissues were set
to 1. Day 11 values in CXCL9 neutralizing ab treated tissues or day 21 values in ISO and CXCL9 neutralizing ab treated tissues
were normalized to 1. *P , 0.05 for CXCL9 neutralizing vs. ISO abs.
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CD4+ T cells.26,39 Thus, CXCL9 may down-regulate HIV-1
replication by decreasing the activation phenotype of HIV-1
target cells. This hypothesis is supported by our published data
demonstrating enhanced HIV-1 replication in CTs, which is
associated with increased immune cell activation marker
expression.18 Furthermore, decreasing mucosal inflammation
by depressing NFkB signaling lowered HIV-1 replication.7
To test whether CXCL9 neutralization reduces mucosal
immune cell activation, we evaluated the impact of blocking
CXCL9 on CD4, CCR5, and CD38 RNA expression by
reverse transcriptase polymerase chain reaction on days 3 and
5 after infection. Selection of these time points allowed
evaluation of gene transcription after immune cell activation
before T-cell depletion by HIV-1.18,40,41
On day 3, we detected a transient increase in CD4 (P =
0.0002), CCR5 (P = 0.0018), and CD38 (P = 0.03) RNA
expression in CXCL9 neutralizing ab compared with isotype
control–treated tissues (Figs. 2A–C), which was associated
with similar levels of HIV-1 transcription (Fig. 2D). On day
5, CD4 (P = 0.0003), CCR5 (P = 0.0005), and CD38 (P =
0.006) RNA expression was decreased in HIV-1–infected
tissues treated with CXCL9 neutralizing ab compared with
isotype control–treated tissues (Figs. 2A–C). Down-
regulation of receptor RNA expression correlated with
decreased HIV-1 RNA production (P = 0.02, Fig. 2D).
HIV-1 Induces CXCL9 Expression, and CXCL9
Neutralization Decreases HIV-1 Replication
in PBMCs
CD4+ immune cells are the primary HIV-1 targets in
mucosal tissues.10 To assess the potential of immune cells as
CXCL9 producers, we evaluated CXCL9 expression in
supernatants from nonactivated HIV-1–infected PBMCs,
which were used as a surrogate of mucosal immune cells.
Supernatants were harvested on days 2 and 5 after infection
and evaluated for CXCL9 levels by ELISA. CXCL9 expres-
sion was significantly enhanced in supernatants from HIV-1–
infected compared with uninfected PBMCs. We detected a 5-
fold and a 1.5-fold increase on days 2 (P = 0.001) and 5 (P =
0.02) after infection, respectively (Fig. 3A).
CXCL9 neutralization decreased HIV-1 p24 levels on
both days 5 (P = 0.05) and 7 (P = 0.006) after infection in
PBMCs (Fig. 3B). Blocking CXCL9 signaling had no direct
effect on either HIV-1 reverse transcription (Fig. 3C) or viral
integration (Fig. 3D).
Blocking CXCL9 Signaling Decreased the
Number of Activated Cervical CD4+ T Cells
Our data suggest that blocking CXCL9 signaling
reduces HIV-1 replication in both CTs and PBMCs (Figs.
1B, 3B). Given that our transcription experiments in CTs
indicated a correlation between decreased HIV-1 transcription
and immune cell activation marker expression (Fig. 2), we
defined the impact of blocking CXCL9 on the activation
phenotype of cervical CD4+ T cells.
Consistent with the results from our transcription experi-
ments (Figs. 2A–C above), CXCL9 neutralization decreased the
number of CD4+ T cells expressing CCR5 and CD38 on day 7
after infection (P = 0.019; Fig. 4B). On day 5, we detected
a transient yet not significant increase in CCR5+ and CD38+
expression on CD4+ T cells in CXCL9 neutralizing compared
with isotype control–treated tissues (P = 0.17; Fig. 4A).
FIGURE 2. Blocking CXCL9 decreases CD4,
CCR5, CD38, and HIV-1 RNA expression in ex
vivo cervical tissues. CD4 (A), CCR5 (B), CD38
(C), and HIV-1 (D) transcription in HIV-1–in-
fected cervical tissues treated with CXCL9
neutralizing or isotype control (ISO) abs was
measured on days 3 and 5 after infection. All
data were normalized to GAPDH. For each
gene, day 3 values in ISO-treated tissues were
set to 1. Day 3 values in CXCL9 neutralizing ab
treated tissues or day 5 values in ISO and
CXCL9 neutralizing ab treated tissues were
normalized to 1. Data are shown as mean6 SD
of 8 donors with each condition tested in
triplicate. *P , 0.05 for CXCL9 neutralizing vs.
ISO abs.
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Blocking CXCL9 Signaling is an Effective
Target to Reduce HIV-1 Replication and
Improve the Anti-HIV-1 Activity of TFV in CTs
To explore the translational/clinical relevance of our
findings, we tested the effect of CXCL9 neutralization as a means
to enhance the efficacy of TFV at suboptimal concentrations. In
these experiments, CTs were left untreated or treated with TFV
at either suboptimal concentrations (10 mg/mL) possibly found in
women with incomplete/inadequate drug use42 or optimal pro-
phylactic concentrations (100 mg/mL) in our experimental
system,18 before infection with HIV-1. Compared with untreated
controls, tissues treated with TFV at 100 mg/mL decreased HIV-
1 p24 levels by 53% (P = 0.003) and 77% (P = 0.00003) on days
11 and 21 after infection, respectively (Fig. 5A). As expected,
tissues treated with this TFV concentration displayed higher
reduction in HIV-1 p24 levels than tissues treated with TFV at
10 mg/mL or those exposed to CXCL9 neutralizing ab (Figs. 5B,
C). By comparing tissues treated with suboptimal concentrations
of TFV and those subjected to CXCL9 neutralization, we found
that TFV at 10 mg/mL lowered HIV-1 p24 levels by 17% (P =
0.01) on day 11 (Fig. 5B), whereas tissues treated with CXCL9
neutralizing ab reduced HIV-1 p24 levels by 42% (Fig. 5C; P =
0.009). On day 21, both treatments decreased HIV-1 p24 release
by 52% (Figs. 5B, C; P = 0.0007 and P = 0.027 for TFV and
CXCL9 neutralization, respectively).
Given that on day 11, CXCL9 neutralization decreased
HIV-1 replication to a greater extent than TFV at 10 mg/mL,
we next tested whether CXCL9 neutralization improved the
anti–HIV-1 activity of suboptimal concentrations of TFV. On
day 11, tissues treated with TFV in combination with CXCL9
neutralizing ab displayed a significant decrease (23%, P =
0.02) in HIV-1 replication compared with those treated with
TFV alone (Fig. 5D). This effect was lost on day 21 (P =
0.309), given that treatment with either TFV at 10 mg/mL or
CXCL9 neutralizing ab displayed similar levels of protection
at this time point (Figs. 5B, C).
DISCUSSION
Mucosal immune responses modulate HIV-1 replication.
Understanding mechanisms of HIV-1 regulation of mucosal
immune responses and identifying novel targets that control HIV-
1 replication in the FGT, the main portal of viral entry in women
after vaginal intercourse43 is critical in the development of
approaches to decrease viral replication and prevent systemic
HIV-1 dissemination. We provide novel insights into the scope
and mechanism of CXCL9 regulation of HIV-1 replication in
CTs, a relevant model of mucosal HIV-1 transmission. HIV-1
enhanced CXCL9 expression, and blocking either constitutive or
HIV-1–induced CXCL9 levels decreased HIV-1 replication in
CTs. Reduced HIV-1 p24 release was the result of lower immune
cell activation, that is, CCR5 and CD38 expression on cervical
CD4+ T cells. Data consistency between CTs and PBMCs
underscores the role of immune cells on CXCL9 production in
CTs and highlights the relevance of CXCL9 signaling on
enhancing HIV-1 replication. When evaluating the anti–HIV-1
activity of CXCL9 neutralization in combination with suboptimal
concentrations of TFV possibly present in poor adherers in
clinical trials,44,45 we detected a greater decrease in HIV-1
FIGURE 3. HIV-1 induces CXCL9
expression and blocking CXCL9 de-
creases HIV-1 replication in PBMCs.
CXCL9 levels in HIV-1–infected
PBMCs were measured on days 2
and 5 after infection (A). The results
from 7 individual experiments eval-
uated in duplicate are shown. For
each experiment, CXCL9 levels were
expressed as fold increase in HIV-1–
infected cells compared with unin-
fected controls set to 1. *P , 0.05
for HIV-1–infected vs. uninfected
PBMCs. HIV-1 p24 (B) expression,
HIV-1 reverse transcription (C) and
viral integration (D) were measured
in HIV-infected PBMCs treated with
CXCL9 neutralizing (CXCL9) or iso-
type control (ISO) abs on days 5 and
7 after infection. At both time
points, HIV-1 p24 levels in CXCL9
neutralizing ab treated tissues were
expressed as fold decrease com-
pared with ISO-treated PBMCs set to
1. For HIV-1 reverse transcription
and integration, all data were nor-
malized to human b actin. Day 5
values in ISO-treated tissues were set
to 1. Day 5 values in CXCL9 neutralizing ab treated tissues or day 7 values in ISO or CXCL9 neutralizing abs treated tissues were
normalized to 1. Data are shown as the mean 6 SD of 3 experiments with each condition tested in triplicate. *P , 0.05 for
CXCL9 neutralizing vs. ISO abs.
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replication in tissues cotreated with TFV and CXCL9 neutraliz-
ing ab compared with those treated with TFV alone at earlier
stages of infection. Thus, targeting mucosal innate immune
responses by blocking CXCL9 signaling may be a relevant
therapeutic approach to down-regulate HIV-1 replication and
potentially reduce viral genital shedding or dissemination to the
periphery when suboptimal concentrations of microbicides such
as TFV are present in the cervicovaginal mucosa.
HIV-1 Infection Enhances CXCL9 Expression
CXCL9 is produced in a wide range of inflammatory
conditions.46,47 In line with epidemiological studies describ-
ing increased CXCL9 levels in the blood, semen, and gut
mucosa of HIV-1–infected treatment-naive patients,27,29 we
demonstrated enhanced CXCL9 expression by HIV-1 in CTs
(Fig. 1A) and PBMCs (Fig. 3A). Although we acknowledge
variations in phenotype between PBMCs and cervical leuko-
cytes, our findings suggest that immune cells may contribute
to CXCL9 expression in CTs.
Blocking CXCL9 Signaling Decreases HIV-1
Replication
Blocking CXCL9 signaling significantly decreased
HIV-1 p24 release in CTs (Fig. 1B) and PBMCs (Fig. 3B),
supporting the hypothesis that CXCL9 promotes HIV-1
replication in immune cells of the FGT. This conclusion is
consistent with studies demonstrating greater genital mucosa
CXCL9 levels in HIV-1–infected compared with uninfected
female sex workers (FSWs) or uninfected control women,
suggesting that CXCL9 expression induces a mucosal micro-
environment that favors HIV-1 replication.48 Furthermore,
HIV-1-exposed seronegative FSWs displayed significant
lower CXCL9 expression compared with HIV-1-
seropositive FSWs,30 implying a potential role of CXCL9 in
the establishment of the infection.
CXCL9 Signaling Decreases the Activation
Phenotype of Mucosal CD4+ T Cells
Knowing that each infected cell harbors 1 copy of
integrated viral DNA,49 and using HIV-1 integration as
a surrogate of the number of infected cells, we saw no effect
of CXCL9 neutralization on HIV-1 integration in either CTs
(Fig. 1D) or PBMCs (Fig. 3D). No difference in the frequency
of HIV-1–infected cells, however, was associated with
decreased HIV-1 p24 release from tissues or cells treated
with CXCL9 neutralizing compared with isotype control abs
(Figs. 1B, 3B), suggesting that, under the settings of CXCL9
neutralization, HIV-1–infected cells produced fewer
viral particles. HIV-1 replication depends on immune cell
FIGURE 4. Blocking CXCL9 decreases
the activation phenotype of CD4+
T cells in ex vivo cervical tissues.
Fluorescence–activated cell sorting
analysis of single cell suspensions from
HIV-1–infected cervical tissues treated
with CXCL9 neutralizing or isotype
control abs. Cells were stained for
CD3, CD8, CCR5, and CD38. CD4+
T cells were defined as CD3+ CD82.
CCR5 and CD38 double positive
CD4+ T cells on days 5 (A) and 7 (B)
after infection are shown. For each
panel in (A and B), the percentage of
CCR5+ and CD38+ double positive
CD4+ T cells is displayed in the upper
right quadrant. This result was con-
sistent among 7 experiments.
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activation,50–52 and CXCL9 induces activation and prolifera-
tion of CD4+ T cells.53 Thus, we evaluated CD4 and immune
activation markers’ CCR5 and CD38 RNA expression in
CTs. Early during the infection, CXCL9 neutralization
enhanced CD4, CCR5, and CD38 RNA levels (Figs. 2A–
C), suggesting an increase in immune cell activation marker
expression likely by additional chemokines such as CXCL10
or CXCL11. This transient increase in receptor expression
was associated with no differences in HIV-1 transcription
(Fig. 2D). In contrast, at later time points, we detected
a significant decrease in CD4, CCR5, and CD38 transcription
in tissues treated with a CXCL9 neutralizing ab compared
with isotype control–treated tissues (Figs. 2A–C) that was
associated with decreased HIV-1 RNA expression. These
findings imply that CXCL9 neutralization down-regulates
HIV-1 replication in CTs by reducing CD4+ T-cell activation.
Supporting our results, it has been demonstrated that
compared with resting T lymphocytes activated CD4+ T cells
are more susceptible to HIV-1 infection.11–13 Findings from
our fluorescence–activated cell sorting experiments demon-
strated a lower frequency of cervical CCR5+ CD38+ CD4+ T
cells in tissues treated with CXCL9 neutralizing compared
with isotype control abs on day 7 after infection (Fig. 4B),
indicating consistency yet different kinetics of RNA and
protein expression of HIV-1 receptor and immune activation
marker expression in CTs.
Our results suggest that CXCL9 down-regulates HIV-1
replication by decreasing immune cell activation in CTs.
Supporting this hypothesis, we have previously demonstrated
that HSV-2, a virus that also induces CXCL9 expression,23
enhances HIV-1 replication by up-regulating CCR5 and
CD38 expression in CTs.18 These findings underscore
a positive correlation between immune cell activation and
HIV-1 production at the site of primary infection.
One limitation of the tissue explant model is that we
cannot evaluate cell recruitment and influx of new cells.31,33
Because CXCL9 induces immune cell recruitment, we are
potentially underestimating the effect of CXCL9 neutraliza-
tion on HIV-1 replication in our model.
Blocking CXCL9 Signaling Improves the Anti-
HIV-1 Activity of Suboptimal Concentrations
of TFV in CTs
Pre-exposure prophylactic regimens containing nucleo-
side reverse transcriptase inhibitors have shown discrepant
results in men who have sex with men, serodiscordant
couples, and women.43,54–58 Although biological factors
cannot be ruled out, these inconsistencies are most likely
attributable to poor adherence resulting in inadequate anti-
retrovirals’ tissue concentrations and protective effects. This
concept has also been cited to explain the discrepant results of
TFV 1% vaginal gel showing 39%, 14%, and 0% effective-
ness under intent to treat analysis in CAPRISA 004, MTN-
003, and FACTS 001 trials, respectively.59–61 Case–cohort
analysis based on returned applicators and/or drug levels,
however, demonstrated protection in 50%–60% of women
who used the gel consistently per protocol.44 These results
underscore the role of adherence in decreasing the efficacy of
TFV.54 Additional data, however, suggest that partial pro-
tection may also have been due to biological factors such as
subclinical inflammation triggered by vaginal infections
known to enhance mucosal susceptibility to HIV-1.7,18 Thus,
alternative and multi target treatments are likely to provide
more efficient preexposure prophylaxis to women.
Given that blocking CXCL9 signaling significantly
reduced HIV-1 replication, we explored the anti-HIV-1
efficacy of CXCL9 neutralization in combination with
FIGURE 5. Anti–HIV-1 activity of TFV
and CXCL9 neutralization alone or in
combination in ex vivo cervical tis-
sues. HIV-1 p24 levels (ng/mL) in su-
pernatants from HIV-1–infected
cervical tissues left untreated or trea-
ted with TFV at either 100 (A) or 10
(B) mg/mL, or with CXCL9 neutraliz-
ing or isotype control abs (C) were
measured by ELISA on days 11 and 21
after infection. Mean values of tripli-
cates from 32 (A), 26 (B), and 34 (C)
individual donors are shown. *P ,
0.05 for untreated vs. TFV-treated
tissues and for CXCL9 neutralizing ab
vs. isotype control–treated tissues.
HIV-1 p24 levels (ng/mL) in super-
natants from HIV-1–infected cervical
tissues treated with TFV at 10 mg/mL
in combination with either CXCL9
neutralizing or isotype control abs (D)
were measured by ELISA on days 11
and 21 after infection. Mean values of triplicates from 12 individual donors are shown. *P , 0.05 for TFV isotype vs. TFV CXCL9
neutralizing abs. Each panel represents a different set of donors. Within each panel, the bars represent the average of the mean
values from all donors.
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TFV at suboptimal concentrations. When TFV concentra-
tions were suboptimal, CXCL9 neutralization decreased
HIV-1 replication to a higher degree than TFV alone early
during the infection (Figs. 5B, C). Indeed a combined
multitarget treatment of TFV at suboptimal concentrations
and CXCL9 neutralizing ab demonstrated an additional
protection compared with the treatment with TFV alone
(Fig. 5D). We have previously demonstrated that TFV at
suboptimal concentrations enhances the frequency of CD4+
T cells early during the infection.38 Thus, CXCL9 reduced
HIV-1 replication, likely by decreasing the immune activa-
tion of CD4+ T cells. This additive effect provides a proof of
concept that understanding the pathogenesis of the initial
HIV-1 mucosal infection and designing specific interven-
tions may be a potential approach to enhance the activity of
topical or systemic prophylactic antiretrovirals. Thus, by
decreasing activation of mucosal CD4+ T cells, CXCL9
neutralization could delay viral spread to the periphery or
reduce HIV-1 genital shedding complementing the antiviral
effects of topical antiretrovirals.
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